国产精品av在线观看不_日韩久久美女毛片_黄色网站在线性爱视频_9691精品人妻无码久久久_成年AV免费网址大全超清_亚洲aⅴ天堂无码_曰本裸色私人影院噜噜噜影院_另类视频无码视频国产精品_网红三级在线播放_美腿丝袜在线观看

Entries by

Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study at the Sleep Research Society’s Conference: Advances in Sleep and Circadian Science

TOKYO and STAMFORD, Conn. – February 4, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, “Purdue Pharma”) today announced six-month results from SUNRISE 2, a long-term Phase 3 clinical study evaluating the efficacy and safety of lemborexant, an investigational agent being developed for the treatment of insomnia, a sleep-wake disorder. Data were presented at the Sleep Research Society’s Advances in Sleep and Circadian Science conference, taking place in Clearwater Beach, Florida, Feb. 1-4, 2019.

2019/2/4 by

SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR FYCOMPA? AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES, AS WELL AS NEW FORMULATION

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has filed a supplementary new drug application in Japan for its in-house discovered antiepileptic drug (AED) Fycompa??(perampanel) seeking approval for use as monotherapy for partial-onset seizures, treatment for partial-onset seizures in pediatric patients aged 4 years and older, as well as a new fine granule formulation.

2019/1/30 by

EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE FOURTH TIME

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been listed in the 2019 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai’s fourth inclusion on the list. Ranked 73rd, Eisai was the highest ranking Japanese company among the eight Japanese companies listed in the Global 100.

2019/1/22 by

2019 Lenvatinib Launching Ceremony Jointly Held by Eisai China and MSD China

On January 12, 2019, Eisai China Holdings Ltd. and MSD China Holding Co., Ltd. jointly held the 2019 Lenvatinib Launching Ceremony (Trademark: Lenvima?) in China, the domestic and foreign experts and scholars in the tumor field gathered together and conducted academic discussions on many issues, and they witnessed the launching of Assistance Project of Liver Cancer Patients.

2019/1/12 by

NEW DRUG APPLICATION FOR PERAMPANEL DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its in-house discovered and developed antiepileptic drug (AED) perampanel (generic name, product name: Fycompa?), for which ?a New Drug Application (NDA) was submitted for review as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older in China in October 2018, has been designated for Priority Review by the National Medical Products Administration (NMPA) due to perampanel’s significant clinical benefit compared to existing treatments.

2019/1/4 by

25 Students from China Medical University Win Eisai China Scholarships and Grants

The 2017-2018 Annual Awards Ceremony for Advanced Collectives and Outstanding Individuals of Undergraduates in China Medical University, held on Nov. 27, 2018, marks the kickoff of the “Eisai China Scholarships” and “Eisai China Grants” that Eisai China Inc. (ECI) provides to seven famous Chinese universities in 2018. Ms. Jun Zheng, ECI’s Senior Regional Manager of NTA Business Unit, Wenge He, Secretary of the Party Committee of the School of Pharmacy of China Medical University, and Xiaoyue Ji, Deputy Director of the Training Center of Rural Doctor of China, presented the awards to the representatives of the students.

2018/11/27 by

EISAI LAUNCHES LENVIMA? (LENVATINIB) IN CHINA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its Chinese subsidiary Eisai China Inc. (ECI) has launched the kinase inhibitor LENVIMA?(product name in China:?樂(lè)衛(wèi)瑪?, generic name: lenvatinib mesylate) in China.

2018/11/12 by

EISAI CHINA COMMENCES FULL-SCALE OPERATION OF NEW SUZHOU PLANT

November 7, 2018, Eisai China Inc. (ECI) held the inauguration ceremony for its new Suzhou plant located at No. 168 Xingpu Road within the Suzhou Industrial Park. Mr. Kazuyuki Katayama (Consulate-General of Japan in Shanghai), Mr. Yue Wang (Commissioner of Jiangsu Food and Drug Administration), Mr. Qingwen Wu (Standing Committee of Suzhou Municipality and Secretary General of the Party Committee of Suzhou Industrial Park Administrative Committee (SIPAC)), Ms. ?Yanyan Sun (Deputy Director of SIPAC), Mr. Jianmin Chen (Director-General of Suzhou Food and Drug Administration), Dr. Haruo Naito (CEO of Eisai Co., Ltd.), Mr. Yasushi Okada (Representative Corporate Officer of ECL, Industry Affairs and China Business), Ms. Yanhui Feng (Vice President of ECL, President of Eisai China), Mr. Norio Kaneko (Chairman of Eisai China) and people with close attention to the development of Eisai China attended the ceremony.

2018/11/7 by

Eisai China Inc. Held the “2018 ADS”

On October 27, 2018, the “2018 ADS” (ADS: Advance Dementia Science) was held by Eisai China Inc. in Beijing, China. The 2018 ADS is a communication platform that Eisai China established for doctors; the forum covers multi-aspects such as basic researches in the cognitive fields, new methods of diagnosis, clinical hotspots, research and development for new drugs, social and government policies, and etc., with well-known professors from China, Japan and South Korea discussing and interacting with over 300 participants on-site and over 400 participators online.?

2018/10/27 by